Delcath Systems, Inc. (NASDAQ:DCTH) Receives $24.50 Average Price Target from Brokerages

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have earned an average rating of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $24.50.

DCTH has been the topic of several recent research reports. Stephens restated an “overweight” rating and set a $25.00 target price on shares of Delcath Systems in a report on Monday, June 23rd. Weiss Ratings restated a “hold (c-)” rating on shares of Delcath Systems in a report on Saturday, September 27th. Wall Street Zen upgraded shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday. Finally, HC Wainwright boosted their price objective on shares of Delcath Systems from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, August 7th.

Delcath Systems Trading Up 4.2%

NASDAQ:DCTH opened at $11.10 on Friday. The firm has a market capitalization of $388.28 million, a price-to-earnings ratio of 222.00 and a beta of 0.84. The firm’s fifty day simple moving average is $10.92 and its 200 day simple moving average is $12.54. Delcath Systems has a twelve month low of $8.08 and a twelve month high of $18.23.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.05. The business had revenue of $24.16 million for the quarter, compared to analyst estimates of $22.84 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. On average, analysts predict that Delcath Systems will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Delcath Systems

A number of institutional investors have recently added to or reduced their stakes in the company. Palisades Investment Partners LLC lifted its holdings in Delcath Systems by 1.0% in the 1st quarter. Palisades Investment Partners LLC now owns 171,084 shares of the company’s stock worth $2,178,000 after buying an additional 1,757 shares in the last quarter. USA Financial Formulas acquired a new position in Delcath Systems in the 2nd quarter worth $25,000. California State Teachers Retirement System bought a new stake in shares of Delcath Systems in the 2nd quarter worth about $26,000. Principal Financial Group Inc. increased its position in shares of Delcath Systems by 2.1% in the 1st quarter. Principal Financial Group Inc. now owns 117,620 shares of the company’s stock worth $1,497,000 after purchasing an additional 2,437 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new stake in shares of Delcath Systems in the 2nd quarter worth about $40,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.